Shell Asset Management CO Denali Therapeutics Inc. Transaction History
Shell Asset Management CO
- $2.9 Billion
- Q2 2025
A detailed history of Shell Asset Management CO transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 4,009 shares of DNLI stock, worth $65,266. This represents 0.0% of its overall portfolio holdings.
Number of Shares
4,009
Previous 4,456
10.03%
Holding current value
$65,266
Previous $61,000
8.2%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding DNLI
# of Institutions
252Shares Held
134MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$214 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$192 Million0.0% of portfolio
-
Baillie Gifford & CO11.6MShares$189 Million0.13% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$107 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$102 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $2.18B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...